Howe & Rusling’s Prestige Consumer Healthcare PBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-84
Closed -$4K 818
2022
Q3
$4K Buy
84
+13
+18% +$720 ﹤0.01% 732
2022
Q2
$4K Sell
71
-8
-10% -$441 ﹤0.01% 716
2022
Q1
$4K Sell
79
-8
-9% -$462 ﹤0.01% 728
2021
Q4
$5K Hold
87
﹤0.01% 683
2021
Q3
$5K Sell
87
-6
-6% -$330 ﹤0.01% 661
2021
Q2
$5K Sell
93
-20
-18% -$961 ﹤0.01% 635
2021
Q1
$5K Sell
113
-27
-19% -$1.13K ﹤0.01% 631
2020
Q4
$5K Buy
140
+57
+69% +$2.02K ﹤0.01% 616
2020
Q3
$3K Buy
83
+34
+69% +$1.26K ﹤0.01% 654
2020
Q2
$2K Buy
+49
New +$1.96K ﹤0.01% 692
2016
Q3
Sell
-118
Closed -$7K 1100
2016
Q2
$7K Hold
118
﹤0.01% 555
2016
Q1
$6K Hold
118
﹤0.01% 638
2015
Q4
$6K Hold
118
﹤0.01% 599
2015
Q3
$5K Hold
118
﹤0.01% 647
2015
Q2
$5K Buy
+118
New +$5.17K ﹤0.01% 653

Other funds holding PBH

Howe & Rusling's PBH Position: Q4 2022 in Review

Howe & Rusling sold out of Prestige Consumer Healthcare (PBH) in Q4 2022, closing a stake of 84 shares — an estimated $4K sold.

Howe & Rusling first reported a position in PBH in Q2 2015 and held it in 15 quarters. The position peaked at $7K in Q2 2016. 289 funds tracked by Wall St. Rank hold PBH as of Q4 2022.

  • Howe & Rusling reported no remaining Prestige Consumer Healthcare position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 84 Prestige Consumer Healthcare shares in Q4 2022, an estimated $4K.
  • Howe & Rusling first reported a position in Prestige Consumer Healthcare in Q2 2015 and held it in 15 quarters.
  • Howe & Rusling's Prestige Consumer Healthcare position peaked at $7K in Q2 2016.
  • 289 funds tracked by Wall St. Rank held Prestige Consumer Healthcare as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.